Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...
Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...
Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...
Miami (July 22, 2025) – The Bronchiectasis and NTM Association announced today that four abstracts using Bronchiectasis and NTM Research Registry data were presented at the World Bronchiectasis ...
Highly symptomatic bronchiectasis patients have increased exacerbation risks, regardless of previous exacerbation history or disease severity. Current guidelines do not recommend preventive treatments ...
Bronchiectasis hospitalizations have higher mortality and costs than COPD and asthma, with a median stay of 5 days and costs of $50,393. During the COVID-19 pandemic, bronchiectasis hospitalizations ...
Please provide your email address to receive an email when new articles are posted on . Diagnosis-related anxiety, depression or fear was reported by a larger proportion of women vs. men. After being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results